A Phase 3 interventional study of Rebif® New Formulation (IFN-beta-1a, RNF) and Placebo in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-07-09.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Merck KGaA, Darmstadt, Germany.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2006, is one of 8 in phase 3, and was the 8th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 200 across the 21 interventional studies, 150 across the 19 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes.
Objectives:
Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF), compared to placebo, in subjects with Relapsing Remitting Multiple Sclerosis and active disease by means of Magnetic Resonance Imaging (MRI) at the end of 16 weeks of treatment Secondary: To evaluate the efficacy of RNF by comparing the mean number of combined unique (CU) lesions per scan per subject between the initial 16 weeks of placebo treatment and 24 weeks of RNF treatment in the same subjects, originally randomized to placebo.
Primary Endpoints: The primary endpoint is the difference between the number of CU active MRI lesions at Week 16 in the RNF group (Group 1) versus the placebo group (Group 2).
Secondary Endpoints: The secondary endpoint is the difference in the mean number of CU active MRI lesions per scan per subject over the following treatment periods: Study Day 1 - Week 16 versus Weeks 17 - 40 for the subjects randomized to Group 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rebif® New Formulation (IFN-beta-1a, RNF)
Drug: Placebo · Drug: Rebif® New Formulation (IFN-beta-1a, RNF)
RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
Also known as: IFN-beta-1a
Matching placebo will be administered subcutaneously three times a week for 16 weeks.
RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
Also known as: IFN-beta-1a
Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16
CU active lesions were defined as a unique newly active or persistently active lesion on the protocol density/time constant 2 (PD/T2) scan or the gadolinium (Gd-) enhanced time constant 1 (T1) scan (with a method to avoid double counting).
Time frame: 16 Weeks
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. AEs were categorized based upon the treatment period during which they occurred, that is, double-blind period (up to Week 16) and rater-blind period (Week 17 up to Week 40).
Time frame: Baseline up to Week 40
Mean Number of CU Lesions Per Scan Between the Initial 16 Weeks of Placebo Treatment and 24 Weeks of RNF Treatment in the Same Participants, Originally Randomized to Placebo.
CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting). Only "Placebo Followed by RNF" arm was evaluable for this outcome measure.
Time frame: Day 1 up to Week 16 and Week 17 up to Week 40
Number of CU Active MRI Lesions
CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting).
Time frame: Up to Week 40
Date of first participant first visit: 15 Dec 2006. Date of last participant last visit: 28 Nov 2008. Twenty five trial centers enrolled participants in the following countries: Bulgaria (7), Canada(2), Estonia (2), Germany (1), Italy(2), Lithuania (1), Romania (1), Russian Federation (4), Serbia (2), and Spain (3).
| Milestone | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF |
|---|---|---|
| Started | 120 | 60 |
| Completed | 109 | 56 |
| Not completed | 11 | 4 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Disease progression | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Participant unable to use rebiject ii | 1 | 0 |
| Withdrew: Participant refused mri | 1 | 0 |
| Withdrew: Inclusion criteria absent | 1 | 0 |
| Withdrew: Non-compliant | 0 | 1 |
| Withdrew: Participant decided to withdraw | 1 | 0 |
| Withdrew: Participant's reason | 0 | 1 |
| Withdrew: Participant decided to stop | 0 | 1 |
CU active lesions were defined as a unique newly active or persistently active lesion on the protocol density/time constant 2 (PD/T2) scan or the gadolinium (Gd-) enhanced time constant 1 (T1) scan (with a method to avoid double counting).
| lesions | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF |
|---|---|---|
| Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 | 0.9 ± 1.4 | 3.0 ± 4.1 |
CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting). Only "Placebo Followed by RNF" arm was evaluable for this outcome measure.
| lesions | Placebo/RNF |
|---|---|
| Day 1 up to Week 16 | 2.31 ± 2.63 |
| Week 17 up to Week 40 | 0.65 ± 0.95 |
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. AEs were categorized based upon the treatment period during which they occurred, that is, double-blind period (up to Week 16) and rater-blind period (Week 17 up to Week 40).
| participants | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF |
|---|---|---|
| AEs during double-blind period (n = 120, 60) | 100 | 39 |
| AEs during rater-blind period (n = 112, 57) | 72 | 43 |
| SAEs during overall period (n = 120, 60) | 4 | 3 |
CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting).
| lesions | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF |
|---|---|---|
| Number of CU Active MRI Lesions | 0.62 ± 1.29 | 1.27 ± 1.33 |
Collected over Baseline up to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rebif® New Formulation (IFN-beta-1a, RNF) | — | 4/120 (3.3%) | 100/120 (83.3%) |
| Placebo/RNF | — | 3/60 (5%) | 39/60 (65%) |
| Event | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF |
|---|---|---|
| Carpal tunnel syndromeNervous system disorders | 0/120 | 1/60 |
| FallInjury, poisoning and procedural complications | 0/120 | 1/60 |
| Joint dislocationInjury, poisoning and procedural complications | 0/120 | 1/60 |
| Back painMusculoskeletal and connective tissue disorders | 0/120 | 1/60 |
| TonsillitisInfections and infestations | 1/120 | 0/60 |
| Pulmonary tuberculosisInfections and infestations | 1/120 | 0/60 |
| Pyelonephritis acuteInfections and infestations | 1/120 | 0/60 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/120 | 0/60 |
| Event | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF |
|---|---|---|
| Influenza like illnessGeneral disorders | 60/120 | 10/60 |
| Injection site erythemaGeneral disorders | 39/120 | 4/60 |
| HeadacheNervous system disorders | 37/120 | 10/60 |
| Injection site painGeneral disorders | 12/120 | 1/60 |
| PyrexiaGeneral disorders | 9/120 | 3/60 |
| AstheniaGeneral disorders | 8/120 | 3/60 |
| ChillsGeneral disorders | 8/120 | 1/60 |
| DizzinessNervous system disorders | 3/120 | 4/60 |
| Upper respiratory tract infectionInfections and infestations | 4/120 | 4/60 |
| FatigueGeneral disorders | 7/120 | 0/60 |
Intent to treat (ITT) population included all randomized participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 120 | 60 | 180 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF | Total |
|---|---|---|---|
| Mean | 34.0 ± 7.8 | 35.2 ± 10.5 | 34.4 ± 8.8 |
| Sex: Female, Male(Participants) | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF | Total |
|---|---|---|---|
| Female | 88 | 42 | 130 |
| Male | 32 | 18 | 50 |
| Region of Enrollment(participants) | Rebif® New Formulation (IFN-beta-1a, RNF) | Placebo/RNF | Total |
|---|---|---|---|
| Bulgaria | 40 | 12 | 52 |
| Canada | 3 | 3 | 6 |
| Estonia | 8 | 5 | 13 |
| Germany | 1 | 0 | 1 |
| Italy | 7 | 4 | 11 |
| Lithuania | 5 | 3 | 8 |
| Romania | 11 | 8 | 19 |
| Russian Federation | 20 | 12 | 32 |
| Serbia | 20 | 9 | 29 |
| Spain | 5 | 4 | 9 |
No study locations are listed for this record.
The record gives a start of Dec 2006, a primary completion of Nov 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →
Merck KGaA, Darmstadt, Germany →